Thomas J Lanza, Jr

This inventor holds 14 USPTO granted patents. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp.. Active years: 1977-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas J Lanza, Jr. Retrieved from https://idiyas.com/inventor/thomas-j-lanza-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14

% Patents Active = 85.7

Average Co-Inventor Count = 5.2

ph-index = 7

Forward Citations = 168(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

Years Active: 1977-2010

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7816534 - Substituted amides (2010-10-19),

2. 7550489 - Substituted pyridyoxy amides (2009-06-23),

3. 6972295 - Substituted amides (2005-12-06),

4. 6204273 - 16-substituted-4-aza-androstane 5-&agr;-reductase isozyme 1 inhibitors (2001-03-20),

5. 5910497 - 16-pyrazinyl-substituted-4-aza-androstane 5-.alpha.-reductase isozyme 1 (1999-06-08),

6. 5821261 - Substituted saturated aza heterocycles as inhibitors of nitric oxide (1998-10-13),

7. 5747485 - Substituted azetidiones as anti-inflammatory and antidegenerative agents (1998-05-05),

8. 5739137 - 16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozyme 1 (1998-04-14),

9. 5719158 - 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors (1998-02-17),

10. 5591737 - Substituted azetidinones as anti-inflammatory and antidegenerative agents (1997-01-07),

11. 4800211 - 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as (1989-01-24),

12. 4621091 - 3-hydroxybenzo[b]thiophene-2-sulfide derivatives compositions, and (1986-11-04),

13. 4131677 - Anti-inflammatory oxazolo [5,4-b]pyridines (1978-12-26),

14. 4038396 - Anti-inflammatory oxazole[4,5-b]pyridines (1977-07-26),

Title: Thomas J Lanza, Jr: Pioneering Innovator in Pharmacology

Introduction:

Thomas J Lanza, Jr, a distinguished inventor based in Edison, NJ, is renowned for his dedication to innovation and his remarkable track record of 14 patents. His cutting-edge contributions have left an indelible mark on the world of inventors, inspiring future generations of innovators.

Latest Patents:

Lanza's latest patents involve novel compounds that act as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor. These compounds have shown remarkable potential in treating a wide range of diseases and conditions, from psychosis to substance abuse disorders and obesity. Their versatility in addressing various ailments showcases Lanza's innovative approach to pharmacology.

Career Highlights:

Having worked for reputable companies like Merck & Company, Inc. and Merck Sharp & Dohme Corporation, Lanza has accumulated a wealth of experience in the field of pharmaceuticals. His expertise and relentless pursuit of groundbreaking solutions have contributed significantly to the development of new drugs and therapies.

Collaborations:

Throughout his career, Lanza has collaborated closely with esteemed professionals in the industry. Notable colleagues include William K Hagmann and Philippe L Durette, who have joined forces with Lanza to push the boundaries of pharmacological research. Their collective efforts have led to unprecedented advancements in drug development.

Conclusion:

In conclusion, Thomas J Lanza, Jr stands out as a pioneering innovator in the realm of pharmacology. His relentless pursuit of innovation, coupled with his impressive patent portfolio, underscores his status as a standout figure in the world of inventors. Lanza's contributions continue to inspire and pave the way for future breakthroughs in the field of pharmaceutical research.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]